Full history for every metric is available with a Kvantra account

Stock profile

Predictive Oncology Inc. (POAI)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Instruments & SuppliesExchange: NASDAQ

Delisted · last close 18 May 2026

Current price
4.68 USD-20.00%
Last close 18 May 2026
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025
Total revenue$m112220
Operating profit$m-28
Net profit$m-26-20-26-14-12-233
EPS reported$-13.37
Operating cashflow per share$-0.57
Capex per share$0.00
FCF per share$-0.57
Free cash flow$m-10
Net debt$m-11
Book value equity$m48
Book value per share$2.74
Number of sharesm17.43
DPS (TTM paid)$0.00

Financial summary

Financials in USD
202020212022202320242025
Value
P/E TTMx-
P/B LTMx2.17
P/S LTMx827.78
P/FCF LTMx-10.41
EV/EBITDA LTMx-0.41
EV/Sales LTMx754.95
Earnings Yield LTM%-224.76%
FCF Yield%-9.60%
Quality
ROE%-488.50%
ROIC%-57.56%
Operating margin%-22688.6%
Gross margin%42.03%
FCF/Sales%-7948.8%
Growth and momentum
EPS Growth YoY%-
Sales Growth YoY%-92.28%
Net Income Growth YoY%-
FCF Growth%-
Operating Profit Growth%-
Dividend and capital structure
Dividend Yield%0.00%
Dividend Growth%0.00%
Payout Ratio%0.00%
FCF/Debtx-5.98
Net Debt/EBITDAx0.04
EBIT/Net interestx0.00
Net debt/market cap%-10.30%
Net debt/Equityx-0.22
Gross debt/equityx0.03

Company overview

Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics division offers extensive clinical diagnostic services, including tumor drug response assessments and genomic profiling, alongside contract research focused on patient-centered drug discovery. This latter service leverages active learning technology for foundational discovery, clinical and translational research, clinical trials, and the development and validation of diagnostics. Meanwhile, the zPREDICTA division excels in crafting organ-specific disease models, providing three-dimensional reconstructions of human tissues that accurately mirror various disease states and simulate drug responses, particularly for evaluating anticancer agents. The Soluble segment delivers services centered on High-Throughput Self-Interaction Chromatography, an automated system proficient at screening additives and excipients in protein formulations to ensure the creation of soluble and physically stable biologic therapeutics. This segment also provides protein stability analysis, specialized kits for swift identification of soluble formulations, and proprietary technologies for the detection and elimination of bacterial endotoxins. The Skyline division markets the STREAMWAY System, a fully automated, wall-mounted device designed to substantially minimize healthcare staff's exposure to blood and other infectious fluids in clinical environments. Furthermore, this division conducts research and development and supplies specialized media that supports the ex-vivo growth of cancer cells while maintaining their original DNA/RNA and proteomic signatures. Founded in 2002, the company was formerly known as Precision Therapeutics Inc. until it adopted the name Predictive Oncology Inc. in June 2019. Its corporate headquarters are situated in Eagan, Minnesota.

WebsiteN/A
IndustryMedical - Instruments & Supplies
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 18 May 2026

Predictive Oncology Inc. (POAI)

POAI · NASDAQ · Healthcare
4.68 USD-20.00%
Benchmarks
Financialsin USD
20242025
About

Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics division offers extensive clinical diagnostic services, including tumor drug response assessments and genomic profiling, alongside contract research focused on patient-centered drug discovery. This latter service leverages active learning technology for foundational discovery, clinical and translational research, clinical trials, and the development and validation of diagnostics. Meanwhile, the zPREDICTA division excels in crafting organ-specific disease models, providing three-dimensional reconstructions of human tissues that accurately mirror various disease states and simulate drug responses, particularly for evaluating anticancer agents. The Soluble segment delivers services centered on High-Throughput Self-Interaction Chromatography, an automated system proficient at screening additives and excipients in protein formulations to ensure the creation of soluble and physically stable biologic therapeutics. This segment also provides protein stability analysis, specialized kits for swift identification of soluble formulations, and proprietary technologies for the detection and elimination of bacterial endotoxins. The Skyline division markets the STREAMWAY System, a fully automated, wall-mounted device designed to substantially minimize healthcare staff's exposure to blood and other infectious fluids in clinical environments. Furthermore, this division conducts research and development and supplies specialized media that supports the ex-vivo growth of cancer cells while maintaining their original DNA/RNA and proteomic signatures. Founded in 2002, the company was formerly known as Precision Therapeutics Inc. until it adopted the name Predictive Oncology Inc. in June 2019. Its corporate headquarters are situated in Eagan, Minnesota.

IndustryMedical - Instruments & Supplies
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free